The expression of neuropeptides in hyperplastic and malignant prostate tissue and its possible clinical implications

Journal of Urology

Volumn 166, Issue 3, 2001, Pages 871-875

  Yu, Dah Shyong ^a   Hsieh, Dar Shih ^a   Chen, Hong I ^a   Chang, Sun Yran ^a  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

Author keywords

Biological; Ploidies; Prostate; Prostatic hyperplasia; Prostatic neoplasms; Tumor markers

Indexed keywords

CHROMOGRANIN A; DNA; NEURON SPECIFIC ENOLASE; NEUROPEPTIDE; PROSTATE SPECIFIC ANTIGEN; SEROTONIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; NEUROSECRETORY CELL; PLOIDY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CARCINOMA; PROSTATE HYPERTROPHY;

EID: 0034891773     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)65854-5     Document Type: Article

References (32)

1. Morphologic and endocrine aspects of prostatic function
2. The development of human benign prostatic hyperplasia with age
3. Androgen and estrogens: Their interaction with stroma and epithelium of human benign prostatic hyperplasia and normal prostate
4. Androgen repressed messages in the rat ventral prostate
5. Androgens modulate epidermal growth factor levels in the rat ventral prostate
6. Binding of epidermal growth factor receptors by human normal, hypertrophic and carcinomatous prostate
7. Expression of transforming growth factors in the rat ventral prostate during castrationinduced programmed cell death
8. Role of transforming growth factor-alpha in human prostate cancer cell growth
9. Effect of transforming growth factor-β1 on proliferation and death of rat prostatic cells
10. The promoter of the prostate- specific antigen gene contains a functional androgen responsive element
11. Peptidehormone and serotonin-immunoreactive tumour cells in carcinoma of the prostate
12. Neuroendocrine differentiation in prostatic carcinoma
13. The endocrine component of prostatic carcinomas, mixed adenocarcinoma-carcinoid tumours and non-tumour prostate. Histochemical and ultrastructural identification of the endocrine cells
14. The course of neuroendocrine differentiation in prostatic carcinomas. An immunohistochemical study testing chromogranin A as an "endocrine marker."
15. Argentaffin cells in prostatic carcinoma: Differentiation from lipofuscin and melanin in prostatic epithelium
16. Characterization of neuroendocrine differentiation in human benign prostate and prostatic adenocarcinoma
17. Neuroendocrine differentiation in carcinoma of the prostate. Diagnostic, prognostic, and therapeutic implications
18. Neuroendocrine cells-a new prognostic parameter in prostate cancer
19. Biochemistry of the chromogranin A protein family
20. Specific endocrine tissue marker defined by a monoclonal antibody
21. Detection of chromogranin in neuroendocrine cells with a monoclonal antibody
22. Secretion of chromogranin A by peptide-producing endocrine neoplasms
23. Elevated serum chromogranin A concentrations in small-cell lung carcinoma
24. Application of DNA flow cytometry to paraffin-embedded archival material for the study of aneuploidy and its clinical significance
25. Flow cytometric DNA analysis in transitional cell carcinoma of urinary bladder: Correlation with histopathology and clinical characteristics
26. Neuroendocrine differentiation in carcinomas of the prostate: Do neuroendocrine serum markers reflect immunohistochemical findings?
27. Neurogenic origin of human prostate endocrine cells
28. Do neuroendocrine cells in human prostate cancer express androgen receptor?
29. Immunoassay and immunohistology studies of chromogranin A as a neuroendocrine marker in patients with carcinoma of the prostate
30. Neuroendocrine cells of the prostate and neuroendocrine differentiation in prostatic carcinoma: A review of morphologic aspects
31. Neuroendocrine differentiation in prostatic carcinoma: An update
32. Prognostic significance of neuroendocrine differentiation in clinically localized prostatic carcinoma